Hemarus Therapeutics Limited, a active public limited company, was established on 16 September 2003 in Shaikpet, Telangana, India. Engaging in biotechnology within the manufacturing sector, it holds CIN: U74220TG2003PLC041698. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹40.00 Cr and a paid-up capital of ₹1.00 M.
Formerly known as Hemarus Therapeutics Private Limited, Credence Clinical Research Private Limited. It upholds a compliant status. Employing 68 professional, Its leadership includes Kavali Dharmendra (Director), Balaraju Jittaboina (Director), Santosh Kumar Surana (Director). Past directors included Pradeep Vasu, Hemang Harish Raja, Seema. It holds no open charges and ₹75.40 Cr settled loans. Its latest AGM occurred on 30 December 2024, with the balance sheet filed on 31 March 2024. It is based at 8-2-293/82/Jiii/359, Plot No.359-Iii, Raod No.80, Jubilee Hills, Shaikpet, Telangana, 500033.
U74220TG2003PLC041698
041698
16 September 2003
₹40.00 Cr
₹1.00 M
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Hemarus Therapeutics Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kavali Dharmendra | Director | 25 Oct 2024 | Current |
| Balaraju Jittaboina | Director | 25 Oct 2024 | Current |
| Santosh Kumar Surana | Director | 25 Oct 2024 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Company Secretary | 27 May 2016 | Past |
| Pramod Abcsdd | Director | 15 Jan 2016 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
| Pramod Abcsdd | Additional Director | 10 May 2019 | Past |
| Pramod Abcsdd | Irp/Rp/Liquidator | 21 Dec 2024 | Past |
| Pramod Abcsdd | Director | 21 Feb 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Hemarus Therapeutics Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 84.64% decrease. The company also saw a substantial fall in profitability, with a 275.8% decrease in profit. The company's net worth observed a substantial decline by a decrease of 73.64%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2022, Hemarus Therapeutics had a promoter holding of 90.54% and a public holding of 9.46%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹754,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Feb 2011 | Indian Overseas Bank | ₹66.68 Cr | Satisfied |
| 10 Aug 2004 | Andhra Pradesh State Financial Corporation | ₹8.72 Cr | Satisfied |
Explore comprehensive loan charge details -
Hemarus Therapeutics has a workforce of 68 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Hemarus Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hemarus Therapeutics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Hemarus Therapeutics Limited last Annual general meeting of members was held on 30 Dec 2024 as per latest MCA records. was documented.
The activity Kavali Dharmendra was appointed as a Director was appointed as a Director on 25 Oct 2024 & has been associated with this company since 1 year 1 month . was completed.
Progress on Balaraju Jittaboina was appointed as a Director was appointed as a Director on 25 Oct 2024 & has been associated with this company since 1 year 1 month . was documented.
Progress on Santosh Kumar Surana was appointed as a Director was appointed as a Director on 25 Oct 2024 & has been associated with this company since 1 year 1 month . was documented.
Progress on Hemarus Therapeutics Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was documented.
The activity A charge registered on 26 Feb 2011 via Charge ID 10280683 with Indian Overseas Bank was fully satisfied on 27 Jan 2021. was completed.
The CIN of Hemarus Therapeutics Limited is U74220TG2003PLC041698.
Hemarus Therapeutics Limited is headquartered at 8-2-293/82/Jiii/359, Plot No.359-Iii, Raod No.80, Jubilee Hills, Shaikpet, Telangana, 500033.
Hemarus Therapeutics Limited was incorporated on 16 September 2003.
The current directors of Hemarus Therapeutics Limited are
The primary industry of Hemarus Therapeutics Limited is Manufacturing.
Hemarus Therapeutics Limited is unlisted.
The authorized capital of Hemarus Therapeutics Limited is ₹40.00 Cr, and the paid-up capital is ₹1.00 M.
The compliance status of Hemarus Therapeutics Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX